Cover Image
市場調查報告書

美國的固態腫瘤檢驗市場:2016∼2020年

Solid Tumor Testing Market in the US 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 353218
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
美國的固態腫瘤檢驗市場:2016∼2020年 Solid Tumor Testing Market in the US 2016-2020
出版日期: 2016年02月24日 內容資訊: 英文 50 Pages
簡介

固態腫瘤檢驗或篩檢為了早期發現癌症而進行,可進行防止癌症細胞擴散全身的有效治療。除了檢查尿和血液等檢體,為了分析特定的遺傳基因變異也有伴隨遺傳基因檢驗的情況。美國的固態腫瘤檢驗市場,預計2016∼2020年以年複合成長率11.1%擴大。

本報告提供美國的固態腫瘤檢驗市場現狀與今後的成長預測、市場趨勢、市場成長的課題、主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

  • 市場焦點

第5章 美國的醫療改革

  • 美國的醫療改革帶給癌症檢驗產業影響

第6章 償付及補償:概要

  • 目前方案:診斷檢驗的評估
  • 美國的報銷問題結構
  • 償付政策的課題

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各技術市場區隔

  • 傳統的檢驗
  • 遺傳基因檢驗

第9章 癌症的各類型市場區隔

  • 乳癌
  • 肺癌
  • 大腸癌
  • 前列腺癌
  • 子宮頸癌
  • 其他

第10章 推動市場的要素

  • 對個人化醫療的高需求
  • 醫療制度的修改
  • 對POC檢驗的需求的增加
  • 分子檢驗的增加

第11章 促進要素的影響

第12章 市場課題

  • 正確的癌症檢測套組的不足
  • 法律規章的課題
  • 熟練技術人員的不足

第13章 促進要素及課題的影響

第14章 市場趨勢

  • 桌面式質譜儀的使用
  • 馬上能使用的試劑

第15章 供應商環境

  • 競爭模式
  • 市場佔有率:2015年
  • 其他值得注意的供應商

第16章 附錄

第17章 關於Technavio

圖表

目錄
Product Code: IRTNTR8803

About Solid Tumor Testing Market in the US

Solid tumor testing or screening is done for the early detection of cancer, enabling effective treatment measures to avoid the spread of cancerous cells throughout the body. The testing procedure involves testing of samples such as urine, blood, and other bodily substances. Further, cancer testing also involves conducting genetic tests to analyze certain gene mutations that are linked to certain cancer types. Biopsy, colonoscopy, Papanicolaou (Pap) test, and fecal occult blood tests are some of the tests that are performed for cancer screening.

Technavio's analysts forecast the solid tumor testing market in the US to grow at a CAGR of 11.1% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of solid tumor testing products, such as assays or kits and bench-top instruments.

The market is divided into the following segments based on cancer types:

  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Other (including pancreatic cysts and thyroid nodules)

Technavio's report, Solid Tumor Testing Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Abbott Molecular
  • Agilent Technologies (Dako)
  • Beckman Coulter
  • Roche Diagnostics

Other Prominent Vendors

  • 20/20 GeneSystems
  • Adaptive Biotechnologies
  • Advanced Cell Diagnostics
  • Affymetrix
  • Agena Bioscience
  • Ambry Genetics
  • ApoCell
  • Avant Diagnostics
  • Biological Dynamics
  • Boditech Med
  • Becton, Dickinson and Company (BD)
  • Biocare Medical
  • Bio-Rad Laboratories
  • Castle Biosciences
  • CDx Diagnostics
  • Celerus Diagnostics
  • Cancer Genetics
  • Caris Life Sciences
  • Clarient Diagnostic Services
  • DiaTech Oncology
  • Enzo Biochem
  • Epic Sciences
  • EDP Biotech
  • Eutropics Pharmaceuticals
  • Fujirebio Diagnostics
  • Genalyte
  • Hologic
  • Janssen Diagnostics
  • Myriad Genetics
  • Omnyx
  • OxfordGene Technology
  • Oncospire Genomics
  • OncoCyte
  • OvaGene Oncology
  • Pathway Genomics
  • Quest Diagnostics
  • QIAGEN
  • RiboMed Biotechnologies
  • Sequenom
  • Siemens Healthcare Diagnostics
  • Thermo Fisher Scientific
  • Tosoh Bioscience
  • TrimGen

Market driver

  • High demand for personalized medicines
  • For a full, detailed list, view our report

Market challenge

  • Regulatory issues
  • For a full, detailed list, view our report

Market trend

  • Ready-to-use reagents
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Healthcare reform in US

  • Impact of US healthcare reform on cancer testing industry

PART 06: Reimbursement and coverage: An overview

  • Current scenario: Validating diagnostic tests
  • Reimbursement structure in US
  • Prevailing issues of reimbursement policies

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by technology

  • Conventional testing
  • Genetic testing

PART 09: Market segmentation by cancer type

  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Other

PART 10: Market drivers

  • High demand for personalized medicines
  • Changes in healthcare system
  • Rise in demand for POC testing
  • Increase in molecular testing

PART 11: Impact of drivers

PART 12: Market challenges

  • Shortage of accurate cancer testing kits
  • Regulatory issues
  • Lack of skilled technicians

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Use of bench-top mass spectrometer
  • Ready-to-use reagents

PART 15: Vendor landscape

  • Competitive scenario
  • Key vendor analysis 2015
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 1: Product offerings
  • Exhibit 2: US healthcare infrastructure before and after healthcare reform
  • Exhibit 3: Positive and negative impact of US healthcare reform on market
  • Exhibit 4: Reimbursement perspective healthcare entitles
  • Exhibit 5: Solid tumor testing market in US
  • Exhibit 6: Solid tumor testing market in US 2015-2020 ($ billions)
  • Exhibit 7: Five forcast analysis
  • Exhibit 8: Segmentation of solid tumor testing market in US by technology 2015
  • Exhibit 9: Segmentation of solid tumor testing market in US by technology 2020
  • Exhibit 10: Segmentation of solid tumor testing market in US by technology 2015-2020
  • Exhibit 11: Solid tumor conventional testing market in US 2015-2020 ($ billions)
  • Exhibit 12: Solid tumor generic testing market in US 2015-2020 ($ billions)
  • Exhibit 13: Segmentation of solid tumor testing market in US by cancer type
  • Exhibit 14: Segmentation of solid tumor testing market in US by cancer type 2015
  • Exhibit 15: Segmentation of solid tumor testing market in US by cancer type 2020
  • Exhibit 16: Segmentation of solid tumor testing market in US by cancer type 2015-2020
  • Exhibit 17: Solid tumor testing market in US for breast cancer 2015-2020 ($ billions)
  • Exhibit 18: Solid tumor testing market in US for lung cancer 2015-2020 ($ billions)
  • Exhibit 19: Solid tumor testing market in US for colorectal cancer2015-2020 ($ billions)
  • Exhibit 20: Solid tumor testing market in US for prostate cancer 2015-2020 ($ millions)
  • Exhibit 21: Solid tumor testing market in US for cervical cancer 2015-2020 ($ millions)
  • Exhibit 22: Solid tumor testing market in US for other cancers 2015-2020 ($ millions)
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Abbott Molecular: Key takeaways
  • Exhibit 26: Agilent Technologies (Dako): Key takeaways
  • Exhibit 27: Beckman Coulter: Key takeaways
  • Exhibit 28: Roche Diagnostics: Key takeaways
Back to Top